128 related articles for article (PubMed ID: 32045493)
1. Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects.
Fedyk ER; Zhao L; Koch A; Smithson G; Estevam J; Chen G; Lahu G; Roepcke S; Lin J; Mclean L
Br J Clin Pharmacol; 2020 Jul; 86(7):1314-1325. PubMed ID: 32045493
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men.
Scott G; Ahmad I; Howard K; MacLean D; Oliva C; Warrington S; Wilbraham D; Worthington P
Br J Clin Pharmacol; 2013 Feb; 75(2):381-91. PubMed ID: 22803642
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial.
Roepcke S; Plock N; Yuan J; Fedyk ER; Lahu G; Zhao L; Smithson G
Pharmacol Res Perspect; 2018 Jun; 6(3):e00402. PubMed ID: 29864242
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers.
Naik H; Vakilynejad M; Wu J; Viswanathan P; Dote N; Higuchi T; Leifke E
J Clin Pharmacol; 2012 Jul; 52(7):1007-16. PubMed ID: 21610201
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
Portron A; Jadidi S; Sarkar N; DiMarchi R; Schmitt C
Diabetes Obes Metab; 2017 Oct; 19(10):1446-1453. PubMed ID: 28741871
[TBL] [Abstract][Full Text] [Related]
6. A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys.
Korver W; Carsillo M; Yuan J; Idamakanti N; Wagoner M; Shi P; Xia CQ; Smithson G; McLean L; Zalevsky J; Fedyk ER
J Pharmacol Exp Ther; 2019 Aug; 370(2):182-196. PubMed ID: 31085699
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, pharmacodynamics, safety, tolerability, and mass balance of single and continuous intravenous infusion of SPT-07A in healthy volunteers.
Wang W; Wang Y; Zhao W; Zhong J; Wang Y; Chen X
Eur J Clin Pharmacol; 2020 Jun; 76(6):785-793. PubMed ID: 32147750
[TBL] [Abstract][Full Text] [Related]
8. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
9. A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects.
Hussaini A; Mukherjee R; Berdieva DM; Glogowski C; Mountfield R; Ho PTC
Clin Transl Sci; 2020 Mar; 13(2):337-344. PubMed ID: 31664766
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.
Sivapalasingam S; Kamal M; Slim R; Hosain R; Shao W; Stoltz R; Yen J; Pologe LG; Cao Y; Partridge M; Sumner G; Lipsich L
Lancet Infect Dis; 2018 Aug; 18(8):884-893. PubMed ID: 29929783
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A.
Yin W; Arkilo D; Khudyakov P; Hazel J; Gupta S; Quinton MS; Lin J; Hartman DS; Bednar MM; Rosen L; Wendland JR
Br J Clin Pharmacol; 2021 Dec; 87(12):4756-4768. PubMed ID: 33990969
[TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects.
Sakurai Y; Nishimura A; Kennedy G; Hibberd M; Jenkins R; Okamoto H; Yoneyama T; Jenkins H; Ashida K; Irie S; Täubel J
Clin Transl Gastroenterol; 2015 Jun; 6(6):e94. PubMed ID: 26111126
[TBL] [Abstract][Full Text] [Related]
13. Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.
MacLean DB; Shi H; Faessel HM; Saad F
J Clin Endocrinol Metab; 2015 Dec; 100(12):4579-87. PubMed ID: 26502357
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
15. First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects.
Banfield C; Rudin D; Bhattacharya I; Goteti K; Li G; Hassan-Zahraee M; Brown LS; Hung KE; Pawlak S; Lepsy C
Br J Clin Pharmacol; 2020 Apr; 86(4):812-824. PubMed ID: 31758576
[TBL] [Abstract][Full Text] [Related]
16. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study.
Klaus B; Sachse R; Ammer N; Kelepouris N; Ostrow V
Growth Horm IGF Res; 2020 Jun; 52():101321. PubMed ID: 32325373
[TBL] [Abstract][Full Text] [Related]
18. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
